AbbVie’s Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

 AbbVie’s Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie’s Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

Shots:

  • The approval is based on the P-III clinical trial program including Measure Up 1/2/AD Up that evaluates the efficacy & safety of Rinvoq (qd) as monothx. with TCS vs PBO in 2500+ adults & adolescents with AD
  • In all three studies, the co-primary EPs showed 75% improvement in EASI 75 and vIGA-AD score of 0/1 (clear or almost clear) @16wks. The therapy demonstrated improvements in skin clearance and itch reduction
  • Rinvoq is a JAK inhibitor that is used to treat adults and adolescents aged ≥12yrs. with AD who are not adequately controlled with a systemic treatment or when the use of the therapies is inadvisable

Click here to­ read full press release/ article | Ref: Abbvie | Image: Pharma Live

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post